Pinnacle Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$63.8M Sell
82,512
-1,229
-1% -$941K 0.82% 23
2025
Q4
$64.6M Sell
83,741
-450
-0.5% -$306K 0.83% 23
2025
Q3
$47.3M Buy
84,191
+15,265
+22% +$8.63M 0.63% 33
2025
Q2
$36.2M Sell
68,926
-12,087
-15% -$6.75M 0.52% 44
2025
Q1
$51.4M Buy
81,013
+18,550
+30% +$12.8M 0.75% 24
2024
Q4
$44.5M Sell
62,463
-4,502
-7% -$3.78M 0.6% 30
2024
Q3
$58.8M Buy
66,965
+611
+0.9% +$680K 1% 11
2024
Q2
$69.7M Sell
66,354
-156
-0.2% -$151K 1.09% 15
2024
Q1
$64M Sell
66,510
-455
-0.7% -$433K 1.01% 15
2023
Q4
$58.8M Sell
66,965
-518
-0.8% -$427K 0.99% 11
2023
Q3
$55.5M Sell
67,483
-2,712
-4% -$2.13M 1.03% 10
2023
Q2
$50.4M Sell
70,195
-1,504
-2% -$1.16M 0.88% 16
2023
Q1
$58.9M Sell
71,699
-1,291
-2% -$974K 1.2% 6
2022
Q4
$52.7M Sell
72,990
-527
-0.7% -$389K 1.15% 7
2022
Q3
$50.6M Sell
73,517
-15,171
-17% -$9.55M 1.16% 6
2022
Q2
$52.4M Sell
88,688
-3,013
-3% -$1.96M 1.14% 6
2022
Q1
$64M Sell
91,701
-3,794
-4% -$2.4M 1.13% 8
2021
Q4
$60.3M Sell
95,495
-1,424
-1% -$876K 1.04% 14
2021
Q3
$58.7M Sell
96,919
-2,462
-2% -$1.53M 1.08% 14
2021
Q2
$55.5M Sell
99,381
-1,110
-1% -$562K 1% 15
2021
Q1
$47.5M Sell
100,491
-5,344
-5% -$2.6M 0.91% 19
2020
Q4
$51.1M Sell
105,835
-4,885
-4% -$2.64M 1.04% 16
2020
Q3
$62M Sell
110,720
-2,156
-2% -$1.31M 1.47% 9
2020
Q2
$70.4M Sell
112,876
-6,970
-6% -$3.96M 1.74% 5
2020
Q1
$58.5M Sell
119,846
-21,943
-15% -$9.05M 1.78% 5
2019
Q4
$53.2M Sell
141,789
-13,171
-8% -$4.43M 1.17% 11
2019
Q3
$43M Sell
154,960
-6,944
-4% -$2.05M 1.01% 16
2019
Q2
$50.7M Sell
161,904
-9,312
-5% -$3.1M 1.19% 14
2019
Q1
$70.3M Sell
171,216
-6,236
-4% -$2.57M 1.59% 6
2018
Q4
$66.3M Sell
177,452
-12,699
-7% -$4.65M 1.71% 3
2018
Q3
$76.8M Sell
190,151
-22,689
-11% -$8.64M 1.59% 5
2018
Q2
$73.4M Sell
212,840
-28,203
-12% -$8.82M 1.51% 6
2018
Q1
$83M Sell
241,043
-3,715
-2% -$1.29M 1.63% 6
2017
Q4
$92M Sell
244,758
-19,349
-7% -$7.84M 1.77% 5
2017
Q3
$118M Sell
264,107
-3,424
-1% -$1.63M 2.18% 4
2017
Q2
$131M Sell
267,531
-11,063
-4% -$4.84M 2.53% 2
2017
Q1
$108M Sell
278,594
-8,329
-3% -$3.09M 2.06% 4
2016
Q4
$105M Sell
286,923
-19,060
-6% -$7.25M 2.13% 4
2016
Q3
$123M Sell
305,983
-3,454
-1% -$1.39M 2.47% 2
2016
Q2
$108M Buy
309,437
+620
+0.2% +$239K 2.33% 3
2016
Q1
$111M Buy
308,817
+5,604
+2% +$2.31M 2.38% 3
2015
Q4
$165M Sell
303,213
-14,552
-5% -$7.88M 3.45% 1
2015
Q3
$148M Sell
317,765
-54,474
-15% -$29.3M 3.27% 1
2015
Q2
$190M Sell
372,239
-42,004
-10% -$20.5M 3.53% 1
2015
Q1
$187M Sell
414,243
-36,887
-8% -$15.6M 3.49% 1
2014
Q4
$185M Sell
451,130
-9,560
-2% -$3.76M 3.63% 1
2014
Q3
$166M Sell
460,690
-55,273
-11% -$18.5M 3.38% 1
2014
Q2
$146M Sell
515,963
-29,638
-5% -$8.78M 2.84% 1
2014
Q1
$164M Sell
545,601
-17,899
-3% -$5.51M 3.19% 1
2013
Q4
$155M Sell
563,500
-44,118
-7% -$12.7M 3.03% 1
2013
Q3
$190M Sell
607,618
-15,584
-3% -$4.1M 3.93% 1
2013
Q2
$140M Buy
+623,202
New +$145M 3.15% 1

Other funds holding REGN

Pinnacle Associates's REGN Position: Q1 2026 in Review

Pinnacle Associates reduced its Regeneron Pharmaceuticals (REGN) stake by 1.5% in Q1 2026, selling an estimated $941K and leaving 82,512 shares worth $63.8M. The position accounts for 0.82% of the portfolio, ranked #23.

Pinnacle Associates first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $190M in Q3 2013. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Pinnacle Associates held 82,512 shares of Regeneron Pharmaceuticals worth $63.8M as of Q1 2026.
  • Pinnacle Associates sold 1,229 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $941K.
  • Regeneron Pharmaceuticals made up 0.82% of Pinnacle Associates's portfolio in Q1 2026, its #23 holding.
  • Pinnacle Associates first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Pinnacle Associates's Regeneron Pharmaceuticals position peaked at $190M in Q3 2013.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.